康弘药业：公司KH110（治疗阿尔茨海默症（Alzheimersdisease，AD）正在按计划进行临床研究

Group 1 - The core viewpoint of the article is that Kanghong Pharmaceutical (002773) is progressing with its clinical research for KH110, a treatment for Alzheimer's disease, as planned [1] - The company acknowledges the inherent uncertainties in the outcomes and timelines associated with drug development, clinical trials, review, and approval processes [1] - Investors are advised to make cautious decisions and be aware of investment risks related to the company's ongoing projects [1]